STTK
Shattuck Labs Inc.
$6.00
-$0.10(-1.72%)
60
Overall
60
Value
63
Tech
57
Quality
Market Cap
$443.98M
Volume
127.17K
52W Range
$0.71 - $8.33
Target Price
$12.50
Company Overview
| Mkt Cap | $443.98M | Price | $6.00 |
| Volume | 127.17K | Change | -1.72% |
| P/E Ratio | -9.1 | Open | $6.10 |
| Revenue | $1.0M | Prev Close | $6.10 |
| Net Income | $-48.8M | 52W Range | $0.71 - $8.33 |
| Div Yield | N/A | Target | $12.50 |
| Overall | 60 | Value | 60 |
| Quality | 57 | Technical | 63 |
No chart data available
About Shattuck Labs Inc.
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Sector: Industrials
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK), Novavax (NVAX) and Airsculpt Technologies (AIRS)
Howard Kim•16 days ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
Howard Kim•19 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | STTK | $6.00 | -1.7% | 127.17K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |